In the present study, we suspect that monoclonal antibodies targeting IL-4 and/or IL-13 may inhibit central processes that improve outcomes in patients with or without mixed phenotypes that may have a reduced capacity for response to baseline asthma therapies. Here, IL4 is linked to asthma.